The results presented here extend the findings of recent studies that demonstrated the major clinical significance of baseline TP53 mutational status in ALK+ NSCLC [6,7,8] As in a previous report [8], presence of TP53 mutations in our patients at initial diagnosis was associated with shorter PFS under TKI (Figure 2B) and worse OS (Figure 1A), but did not apparently affect benefit from chemotherapy (Supplementary Figure S1). This evidence concerns the gene TP53 and non-small cell lung carcinoma.